Table 1.

Characterization of control and dabigatran-exposed subjects.

Dabi	n obs	Variable	n	Mean	std dev
no	41860	age nAMD days aAMD days days to AMD dabi days base days study days AMD days	41860 36865 41015 5840 41860 41860 41860 41860	75.3 1041 982 387 0 606 1089 967	7.5 624.7 629.8 380.7 0 300.2 616.1 634.3
yes	41860	age nAMD days aAMD days days to AMD dabi days base days study days AMD days	41860 38399 41511 3810 41860 41860 41860 41860	76.2 1047 1011 562 398 612 1080 1007	6.9 619.5 619.6 417.3 327.0 270.7 620.4 619.7

41860 subjects were identified per group and characterized for age, baseline days (days that subjects had to be free of AMD diagnosis), study days (days after completion of baseline, during which subjects were interrogated for occurrence of AMD) and days on dabigatran.